Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2017
Price : $35 *
At a glance
- Drugs Rigosertib (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 14 Apr 2014 New trial record